Roy Baynes, a director at Natera, Inc. (NASDAQ:NTRA), recently executed several transactions involving the company’s common stock, according to a filing with the Securities and Exchange Commission. On November 15, Baynes sold a substantial amount of shares, totaling $5.44 million. The shares were sold at prices ranging from $144.258 to $149.9788 per share.
In addition to the sales, Baynes acquired shares through the exercise of stock options. These transactions involved acquiring 22,000 shares at $22.83 per share and 15,230 shares at $24.42 per share, amounting to a total of $874,176.
The sales were conducted under a pre-arranged 10b5-1 trading plan, which allows insiders of publicly traded corporations to set up a trading plan for selling stocks they own. Following these transactions, Baynes holds 15,807 shares of Natera.
In other recent news, Natera Inc (NASDAQ:). reported record Q3 revenue of $439.8 million, a 64% year-over-year increase. The company’s gross margins reached a record 62%, and it generated a cash flow of $34.5 million. Based on these robust financial results, Natera revised its full-year revenue guidance upwards to between $1.61 billion and $1.64 billion. The company experienced a significant rise in oncology test volumes, with 137,000 tests performed, which is a 54% increase from the previous year.
In response to these impressive results, TD Cowen, Baird, and Jefferies have shown confidence in Natera by maintaining positive ratings and raising their price targets. TD Cowen raised its price target to $175, Baird to $160, and Jefferies to $182. These firms highlighted Natera’s operational success and the potential for continued growth.
In addition to its financial achievements, Natera reported promising results in predicting overall survival and chemotherapy benefits in colorectal cancer with its Signatera test. The company also noted a strong performance in women’s health, including the launch of the Fetal RhD test. Despite facing challenges with private payers and potential holiday-related disruptions, Natera sees significant growth opportunities ahead with over 100 trials underway.
InvestingPro Insights
The recent insider transactions by Roy Baynes at Natera, Inc. (NASDAQ:NTRA) come at a time when the company’s stock has shown remarkable performance. According to InvestingPro data, Natera has delivered a significant 176.58% return over the past year, with a particularly strong 34.62% gain in the last six months. This aligns with the timing of Baynes’ stock sales, which occurred at prices between $144.258 and $149.9788 per share.
InvestingPro Tips highlight that Natera’s stock price movements are quite volatile, which could explain the director’s decision to execute sales under a pre-arranged 10b5-1 trading plan. Despite this volatility, the company has seen a substantial market cap growth, currently standing at $19.35 billion.
It’s worth noting that while Natera has experienced impressive revenue growth of 54.94% over the last twelve months, with Q3 2024 showing a robust 63.9% quarterly increase, the company is not yet profitable. An InvestingPro Tip indicates that analysts do not anticipate the company will be profitable this year, which may be a factor for investors to consider alongside the strong stock performance.
For those seeking a deeper understanding of Natera’s financial health and market position, InvestingPro offers 14 additional tips, providing a comprehensive analysis for informed investment decisions.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
